Henry N. Young, PhD

home / authors / henry-n-young-phd

Articles

AJMC
June 13th 2024

Innovation, Affordability, Access: Alzheimer Disease Drugs and the Inflation Reduction Act

Niying Li, PhD, MSc Smita Rawal, PhD Henry N. Young, PhD Lorenzo Villa Zapata, PhD

The authors explore the economic impact and accessibility challenges of new Alzheimer disease drugs under the Inflation Reduction Act, with emphasis on Medicare, pricing, and health care equity.

Site Logo
September 1st 2006

Physicians' Perceptions of Relevant Prescription Drug Costs: Do Costs to the Individual Patient or to the Population Matter Most?

William H. Shrank, MD, MSHS George J. Joseph, MS Niteesh K. Choudhry, MD, PhD Henry N. Young, PhD Susan L. Ettner, PhD Peter Glassman, MBBS, MSc Steven M. Asch, MD, MPH Richard L. Kravitz, MD, MSPH

Site Logo
January 15th 2005

Do the Incentives in 3-Tier Pharmaceutical Benefit Plans Operate as Intended? Results From a Physician Leadership Survey

William H. Shrank, MD, MSHS Henry N. Young, PhD Susan L. Ettner, PhD Peter Glassman, MBBS, MSc Steven M. Asch, MD, MPH Richard L. Kravitz

Latest Updated Articles

Opdivo packaging | Image credit: Bristol Myers Squibb
Published: May 9th 2024 | Updated: May 21st 2024
FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors
AJMC Q&A with Dr Kristen Whitney | Background image credit: ipopba - stock.adobe.com
Published: August 28th 2024 | Updated: September 9th 2024
Illuminating the Future: Dr Kristen Whitney on What's Next for Dermoscopy
LDL and Lp(a) | Image credit : Amgen
Published: August 4th 2024 | Updated: September 9th 2024
Who Should Have Lp(a) Levels Tested? Experts Take Sides
ASCERTAIN Data: Oral Decitabine-Cedazuridine Outcomes in MDS
Published: September 3rd 2024 | Updated: September 9th 2024
ASCERTAIN Data: Oral Decitabine-Cedazuridine Outcomes in MDS
Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial
Published: September 3rd 2024 | Updated: September 9th 2024
Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial
Psoriasis | image credit: pimentos – stock.adobe.com.jpg
Published: August 28th 2024 | Updated: September 9th 2024
TYK2 Inhibitor Zasocitinib Shows High Efficacy, Safety in Moderate to Severe Psoriasis

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo